In the last trading session, 1.95 million shares of the Gossamer Bio Inc (NASDAQ:GOSS) were traded, and its beta was 1.90. Most recently the company’s share price was $1.24, and it changed around $0.07 or 5.98% from the last close, which brings the market valuation of the company to $280.99M. GOSS currently trades at a discount to its 52-week high of $1.60, offering almost -29.03% off that amount. The share price’s 52-week low was $0.50, which indicates that the current value has risen by an impressive 59.68% since then. We note from Gossamer Bio Inc’s average daily trading volume that its 10-day average is 1.21 million shares, with the 3-month average coming to 1.47 million.
Gossamer Bio Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.25. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended GOSS as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Gossamer Bio Inc is expected to report earnings per share of -0.17 for the current quarter.
Gossamer Bio Inc (NASDAQ:GOSS) trade information
Instantly GOSS has showed a green trend with a performance of 5.98% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently up 37.08% year-to-date, but still up 21.57% over the last five days. On the other hand, Gossamer Bio Inc (NASDAQ:GOSS) is 27.56% up in the 30-day period. We can see from the shorts that 5.81 million shares have been sold at a short interest cover period of 6.09 day(s).
The consensus price target as assigned by Wall Street analysts is $4, which translates to bulls needing to increase their stock price by 69.0% from its current value. Analyst projections state that GOSS is forecast to be at a low of $2 and a high of $5.
Gossamer Bio Inc (GOSS) estimates and forecasts
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 7.02M in revenue for the current quarter. 6 analysts expect Gossamer Bio Inc to make 3.48M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 11.99%. Gossamer Bio Inc earnings are expected to increase by 76.06% in 2025, but the outlook is positive 26.42% per year for the next five years.
GOSS Dividends
Gossamer Bio Inc’s next quarterly earnings report is expected to be released in March.
Gossamer Bio Inc (NASDAQ:GOSS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 3.29% of Gossamer Bio Inc shares, and 82.69% of them are in the hands of institutional investors. The stock currently has a share float of 85.51%. Gossamer Bio Inc stock is held by 122.0 institutions, with NEA MANAGEMENT COMPANY, LLC being the largest institutional investor. By 2024-06-30, it held 8.0152% of the shares, which is about 18.09 million shares worth $16.3 million.
ARTAL GROUP S.A., with 5.8958% or 13.31 million shares worth $11.99 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024. The former held 7.91 shares worth $9.81 million, making up 3.49% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 7.84 shares worth around $9.72 million, which represents about 3.46% of the total shares outstanding.
